I am negative on the company but the product is working and approval 2019/2020 (if not sooner) if all goes well. According to ISDA there have been no issues to date and with Right-to-Try nearing approval in the USA this will only increase exposure for Chemosat.
No Debt (that we know off) deficit of $320m (in that area), SP under $0.02... A few Smart Business/Marketing people with some long term capital could turn this ship on a dime (In My Opinion).